Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
Jyoti D. Patel, Philip Bonomi, Mark A. Socinski, Ramaswamy Govindan, Shengyan Hong, Coleman Obasaju, Eduardo J. Pennella, Allicia C. Girvan, Susan C. GubaVolume:
10
Year:
2009
Language:
english
DOI:
10.3816/clc.2009.n.035
File:
PDF, 100 KB
english, 2009